Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Usefulness of BRG1 immunostaining in detecting SMARCA4 deficiency in "so-called" cancers of unknown primary in daily pathology practice.

Diagnostic pathology - 1 Dec 2025

Hasegawa Chie, Washimi Kota, Hiroshima Yukihiko, Takahashi Hiroyuki, Sato Shinya, Yoshioka Emi, Okubo Yoichiro, Miyagi Yohei

Abstract excerpt

BACKGROUND: SMARCA4 encodes BRG1, loss of which is associated with aggressive tumor biology. Although SMARCA4 deficiency has been described in various malignancies, its role in “so-called” cancers of unknown primary (“so-called” CUP), that is, metastatic tumors encountered in pathology practice without a clear primary site, remains unclear. METHODS: We retrospectively studied 108 cases submitted as so-called...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to DNA Helicases

Share to Immunohistochemistry

Share to Neoplasms, Unknown Primary

Share to Nuclear Proteins

Share to Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 41327322
DOI: 10.1186/s13000-025-01738-8
PMCID: PMC12777329

Genes

SMARCA4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Usefulness of BRG1 immunostaining in detecting SMARCA4 deficiency in "so-called" cancers of unknown primary in daily pathology practice.PMID 41327322Read ↗

Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.Semantic proximity Read ↗

Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods.Semantic proximity Read ↗

[Clinicopathological analysis of SMARCA4-deficient tumors of digestive system origin].Semantic proximity Read ↗

Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification.Semantic proximity Read ↗

Cancer of unknown primary.Semantic proximity Read ↗

Brain metastases lung adenocarcinoma patients with BRG1 loss have a grim prognosis, featuring unique morphological and methylation characteristics.Semantic proximity Read ↗

[Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].Semantic proximity Read ↗

Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary.Semantic proximity Read ↗

Primary SMARCB1-deficient intestinal carcinoma: Clinicopathological and molecular characterization of three cases with analysis of published data.Semantic proximity Read ↗

Cancer of unknown primary: the evolution of tissue of origin identification in the artificial intelligence eraSemantic proximity Read ↗

Perspectives and Issues in the Assessment of SMARCA4 Deficiency in the Management of Lung Cancer Patients.Semantic proximity Read ↗

Successful Identification and Treatment of Cancer of Unknown Primary Originating from Gastric Cancer Using Comprehensive Genomic Profiling and Immune Checkpoint Inhibitor TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.